ReviewSignal transduction and targeted therapy2026
Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The endo-lysosomal-lipid axis: bidirectional interactions between membrane trafficking dysfunction and lipid metabolic disorders.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Autophagy is a tightly regulated catabolic process that is essential for cellular homeostasis, stress adaptation, and metabolic balance. Its dysregulation has been implicated in a wide range of diseases, including cancer, neurodegenerative disorders, metabolic syndromes, muscular diseases, and infections. Recent studies have revealed the central roles of transcription factors, including TFEB, FOXO family members, p53, and NF-κB, in orchestrating autophagy through their direct regulation of lysosome-related genes. These factors often interact with epigenetic regulators such as histone acetyltransferases, deacetylases, and methyltransferases, which fine-tune chromatin accessibility and transcriptional output. Dysregulation of these pathways leads to aberrant autophagy and contributes to pathogenesis. Emerging therapeutic strategies targeting these transcriptional and epigenetic regulators have shown promise in preclinical and clinical settings, although challenges remain owing to the context-specific roles of autophagy in promoting either cell survival or cell death or contributing to protein aggregation and metabolic imbalance, depending on the disease. Clinical trials with autophagy modulators, including mTOR inhibitors, HDAC inhibitors, SIRT1 activators, and TFEB agonists, have yielded variable outcomes, emphasizing the need for precision medicine approaches. Advances in nanomedicine and biomaterials provide innovative delivery platforms that increase the specificity, bioavailability, and tissue targeting ability of autophagy-targeting agents. This review provides a comprehensive and detailed synthesis of how transcriptional and epigenetic regulators control autophagy across physiological and pathological contexts. In addition, we discuss therapeutic efforts, challenges in clinical translation, and future directions, including biomarker discovery, combinatorial treatment strategies, and targeted delivery systems, to enable more effective modulation of autophagy in disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.